Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
Paula Schwartz Edna Kaplan Jessica Breu Daniel Vitt Fund Immunic Into The Fourth Quarter Rx Communications Group
Source: prnewswire.com